ALEX DELROSARIO: Open Payments
NPI 1336248145 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,701 in 118 payments from 12 companies in 2025. Trend: 2023 $1,261 · 2024 $1,826 · 2025 $2,701
Food & beverage: $2,701
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 20 | $404 |
| Alkermes, Inc. | 16 | $393 |
| ABBVIE INC. | 15 | $314 |
| E.R. Squibb & Sons, L.L.C. | 16 | $308 |
| Neurocrine BioSciences, Inc. | 11 | $279 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $272 |
| Vanda Pharmaceuticals Inc. | 8 | $219 |
| Lundbeck LLC | 9 | $191 |
| Almatica Pharma LLC | 6 | $141 |
| Inspire Medical Systems, Inc. | 1 | $84 |
Products named: REXULTI, ARISTADA, VRAYLAR, COBENFY, INGREZZA, CAPLYTA, FANAPT, LOREEV XR.
Industry payments across NV — which companies pay providers there.
